Literature DB >> 15528719

Type III secretion phenotypes of Pseudomonas aeruginosa strains change during infection of individuals with cystic fibrosis.

Manu Jain1, Daniel Ramirez, Roopa Seshadri, Joanne F Cullina, Catherine A Powers, Grant S Schulert, Maskit Bar-Meir, Christine L Sullivan, Susanna A McColley, Alan R Hauser.   

Abstract

Pseudomonas aeruginosa is a frequent cause of respiratory exacerbations in individuals with cystic fibrosis. An important virulence determinant of this pathogen is its type III protein secretion system. In this study, the type III secretion properties of 435 P. aeruginosa respiratory isolates from 56 chronically infected individuals with cystic fibrosis were investigated. Although it had been previously reported that 75 to 90% of P. aeruginosa isolates from patients with hospital-acquired pneumonia secreted type III proteins, only 12% of isolates from cystic fibrosis patients did so, with nearly all of these isolates secreting ExoS and ExoT but not ExoU. Despite the low overall prevalence of type III protein-secreting isolates, at least one secreting isolate was cultured from one-third of cystic fibrosis patients. Interestingly, the fraction of cystic fibrosis patient isolates capable of secreting type III proteins decreased with duration of infection. Although 90% of isolates from the environment, the presumed reservoir for the majority of P. aeruginosa strains that infect patients with cystic fibrosis, secreted type III proteins, only 49% of isolates from newly infected children, 18% of isolates from chronically infected children, and 4% of isolates from chronically infected adults with cystic fibrosis secreted these proteins. Within individual patients, isolates of clonal origin differed in their secretion phenotypes, indicating that as strains persisted in cystic fibrosis patient airways, their type III protein secretion properties changed. Together, these findings indicate that following infection of cystic fibrosis patient airways, P. aeruginosa strains gradually change from a type III protein secretion-positive phenotype to a secretion-negative phenotype.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15528719      PMCID: PMC525189          DOI: 10.1128/JCM.42.11.5229-5237.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  58 in total

1.  Ras effector pathway activation by epidermal growth factor is inhibited in vivo by exoenzyme S ADP-ribosylation of Ras.

Authors:  M L Henriksson; R Rosqvist; M Telepnev; H Wolf-Watz; B Hallberg
Journal:  Biochem J       Date:  2000-04-01       Impact factor: 3.857

2.  The amino-terminal domain of Pseudomonas aeruginosa ExoS disrupts actin filaments via small-molecular-weight GTP-binding proteins.

Authors:  K J Pederson; A J Vallis; K Aktories; D W Frank; J T Barbieri
Journal:  Mol Microbiol       Date:  1999-04       Impact factor: 3.501

3.  Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis.

Authors:  R L Henry; C M Mellis; L Petrovic
Journal:  Pediatr Pulmonol       Date:  1992-03

4.  ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury.

Authors:  V Finck-Barbançon; J Goranson; L Zhu; T Sawa; J P Wiener-Kronish; S M Fleiszig; C Wu; L Mende-Mueller; D W Frank
Journal:  Mol Microbiol       Date:  1997-08       Impact factor: 3.501

5.  Pseudomonas aeruginosa induces type-III-secretion-mediated apoptosis of macrophages and epithelial cells.

Authors:  A R Hauser; J N Engel
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

6.  ADP-ribosylation of oncogenic Ras proteins by pseudomonas aeruginosa exoenzyme S in vivo.

Authors:  T S Vincent; J E Fraylick; E M McGuffie; J C Olson
Journal:  Mol Microbiol       Date:  1999-06       Impact factor: 3.501

7.  Interruption of multiple cellular processes in HT-29 epithelial cells by Pseudomonas aeruginosa exoenzyme S.

Authors:  J C Olson; J E Fraylick; E M McGuffie; K M Dolan; T L Yahr; D W Frank; T S Vincent
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

8.  Intracellular targeting of exoenzyme S of Pseudomonas aeruginosa via type III-dependent translocation induces phagocytosis resistance, cytotoxicity and disruption of actin microfilaments.

Authors:  E Frithz-Lindsten; Y Du; R Rosqvist; A Forsberg
Journal:  Mol Microbiol       Date:  1997-09       Impact factor: 3.501

9.  Isolation and characterization of transposon-induced mutants of Pseudomonas aeruginosa deficient in production of exoenzyme S.

Authors:  T I Nicas; B H Iglewski
Journal:  Infect Immun       Date:  1984-08       Impact factor: 3.441

10.  Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic.

Authors:  K Cheng; R L Smyth; J R Govan; C Doherty; C Winstanley; N Denning; D P Heaf; H van Saene; C A Hart
Journal:  Lancet       Date:  1996-09-07       Impact factor: 79.321

View more
  67 in total

1.  Genotypic and phenotypic variation in Pseudomonas aeruginosa reveals signatures of secondary infection and mutator activity in certain cystic fibrosis patients with chronic lung infections.

Authors:  Ashley E Warren; Carla M Boulianne-Larsen; Christine B Chandler; Kami Chiotti; Evgueny Kroll; Scott R Miller; Francois Taddei; Isabelle Sermet-Gaudelus; Agnes Ferroni; Kathleen McInnerney; Michael J Franklin; Frank Rosenzweig
Journal:  Infect Immun       Date:  2011-09-19       Impact factor: 3.441

2.  In vivo discrimination of type 3 secretion system-positive and -negative Pseudomonas aeruginosa via a caspase-1-dependent pathway.

Authors:  Tamding Wangdi; Lilia A Mijares; Barbara I Kazmierczak
Journal:  Infect Immun       Date:  2010-09-07       Impact factor: 3.441

Review 3.  Innate Immune Signaling Activated by MDR Bacteria in the Airway.

Authors:  Dane Parker; Danielle Ahn; Taylor Cohen; Alice Prince
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

4.  Multiple sensors control reciprocal expression of Pseudomonas aeruginosa regulatory RNA and virulence genes.

Authors:  Isabelle Ventre; Andrew L Goodman; Isabelle Vallet-Gely; Perrine Vasseur; Chantal Soscia; Søren Molin; Sophie Bleves; Andrée Lazdunski; Stephen Lory; Alain Filloux
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-22       Impact factor: 11.205

5.  Evolving stealth: genetic adaptation of Pseudomonas aeruginosa during cystic fibrosis infections.

Authors:  Dao Nguyen; Pradeep K Singh
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-22       Impact factor: 11.205

6.  Direct interaction between sensor kinase proteins mediates acute and chronic disease phenotypes in a bacterial pathogen.

Authors:  Andrew L Goodman; Massimo Merighi; Mamoru Hyodo; Isabelle Ventre; Alain Filloux; Stephen Lory
Journal:  Genes Dev       Date:  2009-01-15       Impact factor: 11.361

7.  In vitro assays to monitor the activity of Pseudomonas aeruginosa Type III secreted proteins.

Authors:  Stephanie L Rolsma; Dara W Frank
Journal:  Methods Mol Biol       Date:  2014

8.  Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes.

Authors:  Nicole Mayer-Hamblett; Margaret Rosenfeld; Ronald L Gibson; Bonnie W Ramsey; Hemantha D Kulasekara; George Z Retsch-Bogart; Wayne Morgan; Daniel J Wolter; Christopher E Pope; Laura S Houston; Bridget R Kulasekara; Umer Khan; Jane L Burns; Samuel I Miller; Lucas R Hoffman
Journal:  Am J Respir Crit Care Med       Date:  2014-08-01       Impact factor: 21.405

9.  In situ growth rates and biofilm development of Pseudomonas aeruginosa populations in chronic lung infections.

Authors:  Lei Yang; Janus A J Haagensen; Lars Jelsbak; Helle Krogh Johansen; Claus Sternberg; Niels Høiby; Søren Molin
Journal:  J Bacteriol       Date:  2007-12-21       Impact factor: 3.490

10.  Evolution of Pseudomonas aeruginosa type III secretion in cystic fibrosis: a paradigm of chronic infection.

Authors:  Manu Jain; Maskit Bar-Meir; Susanna McColley; Joanne Cullina; Eileen Potter; Cathy Powers; Michelle Prickett; Roopa Seshadri; Borko Jovanovic; Argyri Petrocheilou; John D King; Alan R Hauser
Journal:  Transl Res       Date:  2008-10-31       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.